Review anchor
Gamma-aminobutyric acid receptor subunit alpha-2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Gamma-aminobutyric acid receptor subunit alpha-2
CHEMBL4956
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Gamma-aminobutyric acid receptor subunit alpha-2 as ChEMBL target CHEMBL4956, mapped to UniProt P47869. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4956
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P47869
Gamma-aminobutyric acid receptor subunit alpha-2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Gamma-aminobutyric acid receptor subunit alpha-2 matters
Gamma-aminobutyric acid receptor subunit alpha-2 is reviewed as Gamma-aminobutyric acid receptor subunit alpha-2 (UniProt P47869); Gamma-aminobutyric acid receptor subunit alpha-2 shows approved-linked disease relevance led by anxiety. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 189 compounds, and 25 assays, with lead potency reaching pChEMBL 9.5.
Protein context
Gamma-aminobutyric acid receptor subunit alpha-2
Gamma-aminobutyric acid receptor subunit alpha-2 Sequence length is 451 aa.
Review this target as Gamma-aminobutyric acid receptor subunit alpha-2, mapped to UniProt P47869. Sequence length is 451 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P47869
Protein
Disease context
anxiety
Gamma-aminobutyric acid receptor subunit alpha-2 shows approved-linked disease relevance led by anxiety. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AZD6280, AZD7325, BROMAZEPAM.
Start review with anxiety because it currently carries approved-linked support. Linked drugs include AZD6280, AZD7325, BROMAZEPAM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
3 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 4 approved drugs, 189 compounds, and 25 assays for this target. The dominant activity type is KI. CHEMBL1783282 is the current potency anchor at pChEMBL 9.5.
Use CHEMBL1783282 as the tractability anchor when discussing potency (pChEMBL 9.5).
Activity source · ChEMBL 36 via Core Engine
4 approved
pChEMBL 9.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Gamma-aminobutyric acid receptor subunit alpha-2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P47869, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why anxiety is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
189
Total Compounds
25
Total Assays
4
Approved Drugs
IC50: 20.0, KI: 107.0, EC50: 30.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1783282
|
9.5 | Ki | Clinical |
|
|
No preferred name
CHEMBL44533
|
9.5 | Ki | — |
|
|
No preferred name
CHEMBL306422
|
9.2 | Ki | — |
|
|
No preferred name
CHEMBL45198
|
9.2 | Ki | — |
|
|
No preferred name
CHEMBL373250
|
9.2 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ZOLPIDEM
CHEMBL911
|
1992 |
|
|
FLUMAZENIL
CHEMBL407
|
1991 |
|
|
ALPRAZOLAM
CHEMBL661
|
1981 |
|
|
DIAZEPAM
CHEMBL12
|
1963 |
Source Header